SGLT2抑制剂通过Na+/H+交换体发挥心脏保护作用的研究进展

doi:10.3969/j.issn.1003-9198.2025.06.017

Abstract

Abstract: As research on sodium-glucose cotransporter 2 (SGLT2) inhibitors deepens and clinical benefits become evident, SGLT2 inhibitors have been gradually included in guidelines for heart failure management, although their mechanisms of cardioprotective effect remain not fully understood. The Na⁺/H⁺ exchanger (NHE) plays a crucial role in the cardioprotective effects of SGLT2 inhibitors, and NHE has also become an important target for drug intervention in cardiac hypertrophy and myocardial ischemia-reperfusion. This article reviews the role of NHE in cardiovascular function and its mechanism in the cardioprotective effects of SGLT2 inhibitors.

Key words: sodium-glucose cotransporter 2, Na⁺/H⁺ exchanger, heart failure

CLC Number:

R541

ZHANG Xinlu, HE Huiwei. Research progress on the cardioprotective effect of SGLT2 inhibitors through Na⁺/H⁺ exchanger[J]. Practical Geriatrics, 2025, 39(6): 617-620.

References

[1] 中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024,52(03):235-275.
[2] SAVARESE G, BECHER P M, LUND L H, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology[J]. Cardiovasc Res, 2023,118(17):3272-3287.
[3] 马丽媛, 王增武, 樊静, 等. 《中国心血管健康与疾病报告2022》要点解读[J]. 中国全科医学, 2023,26(32):3975-3994.[4] 葛均波, 霍勇, 杨杰孚, 等. 慢性心力衰竭“新四联”药物治疗临床决策路径专家共识[J]. 中国循环杂志, 2022,37(8):769-781.
[5] HEIDENREICH P A, BOZKURT B, AGUILAR D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J]. J Am Coll Cardiol, 2022, 79(17): e263-e421.
[6] ZINMAN B, WANNER C, LACHIN J M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015,373(22):2117-2128.
[7] MCMURRAY J J V, SOLOMON S D, INZUCCHI S E, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019,381(21):1995-2008.
[8] SOLOMON S D, MCMURRAY J, CLAGGETT B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med, 2022,387(12):1089-1098.
[9] COX Z L, COLLINS S P, HERNANDEZ G A, et al. Efficacy and safety of dapagliflozin in patients with acute heart failure[J]. J Am Coll Cardiol, 2024,83(14):1295-1306.
[10] FLIEGEL L. Structural and functional changes in the Na⁺/H⁺ exchanger isoform 1, induced by Erk1/2 phosphorylation[J]. Int J Mol Sci, 2019,20(10):2378.
[11] ORLOWSKI J, GRINSTEIN S. Na⁺/H⁺ exchangers[J]. Compr Physiol, 2011,1(4):2083-2100.
[12] LI T, TUO B. Pathophysiology of hepatic Na⁺/H⁺ exchange (Review)[J]. Exp Ther Med, 2020,20(2):1220-1229.
[13] LU M, JIA M, WANG Q, et al. The electrogenic sodium bicarbonate cotransporter and its roles in the myocardial ischemia-reperfusion induced cardiac diseases[J]. Life Sci, 2021,270:119153.
[14] PARKER M D, MYERS E J, SCHELLING J R. Na⁺-H⁺ exchanger-1 (NHE1) regulation in kidney proximal tubule[J]. Cell Mol Life Sci, 2015,72(11):2061-2074.
[15] LI X, KARKI P, LEI L, et al. Na⁺/H⁺ exchanger isoform 1 facilitates cardiomyocyte embryonic stem cell differentiation[J]. Am J Physiol Heart Circ Physiol, 2009,296(1):H159-H170.
[16] FLIEGEL L. Regulation of the Na⁺/H⁺ exchanger in the healthy and diseased myocardium[J]. Expert Opin Ther Targets, 2009,13(1):55-68.
[17] SHIMIZU I, MINAMINO T. Physiological and pathological cardiac hypertrophy[J]. J Mol Cell Cardiol, 2016,97:245-262.
[18] SULEIMAN M, ABDULRAHMAN N, YALCIN H, et al. The role of CD44, hyaluronan and NHE1 in cardiac remodeling[J]. Life Sci, 2018,209:197-201.
[19] MEDINA A J, PINILLA O A, PORTIANSKY E L, et al. Silencing of the Na⁺/H⁺ exchanger 1(NHE-1) prevents cardiac structural and functional remodeling induced by angiotensin Ⅱ[J]. Exp Mol Pathol, 2019,107:1-9.
[20] KAWASE H, BANDO Y K, NISHIMURA K, et al. A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis[J]. J Mol Cell Cardiol, 2016,98:37-47.
[21] BOZKURT B, AHMAD T, ALEXANDER K M, et al. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America[J]. J Card Fail,2023,29(10):1412-1451.
[22] LAMBERT R, SRODULSKI S, PENG X, et al. Intracellular Na⁺ concentration ([Na⁺] i) is elevated in diabetic hearts due to enhanced Na⁺-glucose cotransport[J]. J Am Heart Assoc, 2015,4(9):e002183.
[23] BAARTSCHEER A, SCHUMACHER C A, WUST R C I, et al. Empagliflozin decreases myocardial cytoplasmic Na⁺ through inhibition of the cardiac Na⁺/H⁺ exchanger in rats and rabbits[J]. Diabetologia, 2017,60(3):568-573.
[24] UTHMAN L, BAARTSCHEER A, BLEIJLEVENS B, et al. Class effects of sglt2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na⁺/H⁺ exchanger, lowering of cytosolic Na⁺ and vasodilation[J]. Diabetologia, 2018,61(3):722-726.
[25] CHUNG Y J, PARK K C, TOKAR S, et al. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na⁺/H⁺ exchanger-1 or lower [Na⁺] i in the heart[J]. Cardiovasc Res, 2021,117(14):2794-2806.
[26] KIM I, CHO H J, LIM S, et al. Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction[J]. Exp Mol Med, 2023,55(6):1174-1181.
[27] XU Y, ZHANG C, JIANG K, et al. Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria[J]. Acta Pharm Sin B, 2023,13(4):1671-1685.
[28] TRUM M, RIECHEL J, SCHOLLMEIER E, et al. Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF[J]. Cardiovasc Res, 2024,120(9):999-1010.[29] MARTINEZ E C, PASSARIELLO C L, LI J, et al. RSK3: a regulator of pathological cardiac remodeling[J]. IUBMB Life, 2015,67(5):331-337.
[30] MAEKAWA N, ABE J, SHISHIDO T, et al. Inhibiting p90 ribosomal S6 kinase prevents (Na⁺)-H⁺ exchanger-mediated cardiac ischemia-reperfusion injury[J]. Circulation, 2006,113(21):2516-2523.
[31] CHEN S, OVERBERG K, GHOUSE Z, et al. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition[J]. Biomed Pharmacother, 2024,174:116477.
[32] ZHOU H, WANG S, ZHU P, et al. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission[J]. Redox Biol, 2018,15:335-346.
[33] NAKAO M, SHIMIZU I, KATSUUMI G, et al. Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload[J]. Sci Rep, 2021,11(1):18384.
[34] UTHMAN L, HOMAYR A, JUNI R P, et al. Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor α-stimulated human coronary arterial endothelial cells[J]. Cell Physiol Biochem, 2019,53(5):865-886.
[35] GUO H, YU X, LIU Y, et al. Sglt2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant[J]. Sci Transl Med, 2023,15(680):eabp9952.
[36] UTHMAN L, LI X, BAARTSCHEER A, et al. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na⁺] _c/ROS-pathway in human endothelial cells[J]. Biomed Pharmacother, 2022,146:112515.
[37] CHUNG C C, LIN Y K, CHEN Y C, et al. Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis[J]. Cardiovasc Diabetol, 2023,22(1):27.

Research progress on the cardioprotective effect of SGLT2 inhibitors through Na⁺/H⁺ exchanger

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

[1]	CHEN Bukuan, WAN Zhen, XU Kangshi. Prospective randomized controlled study of the combination therapy of sacubitril/valsartan and cyclic adenosine monophosphate in elderly patients with heart failure with reduced ejection fraction [J]. Practical Geriatrics, 2025, 39(5): 487-491.
[2]	YE Jiaqi, YAN Xiaoyun, JIANG Ying, CHEN Yun, ZHANG Qing. Predictive value of laminin level for the prognosis of acute heart failure [J]. Practical Geriatrics, 2025, 39(4): 391-394.
[3]	ZHAO Shuqing, ZHAO Ying, ZHANG Yu, LU Xiaohui. A review of cellular senescence in chronic heart failure [J]. Practical Geriatrics, 2025, 39(1): 93-97.
[4]	WANG Xiaojiao, WANG Ning, CUI Hong, YE Tong, WANG Xiaoming. Influence of exercise rehabilitation in elderly patients with mild to moderate chronic heart failure [J]. Practical Geriatrics, 2024, 38(8): 775-778.
[5]	ZHANG Jingjing, ZHU Xiaoxia, YAO Chunlei, WANG Wei. Correlation between control nutritional status score and heart failure in elderly patients with coronary artery disease [J]. Practical Geriatrics, 2024, 38(7): 697-700.
[6]	YU Wenhui, ZHU Huanhuan, CHEN Qiuju, ZHU Di, CHEN Yan. Behavioral experience of home management of volume overload in elderly patients with chronic heart failure based on COM-B theory: a qualitative study [J]. Practical Geriatrics, 2024, 38(6): 625-628.
[7]	LIU Lin, WU Qing, ZHANG Jing, MAO Fangying, YU Lu, REN Yiting, FANG Ting. Status and influencing factors of symptom perception in elderly patients with heart failure [J]. Practical Geriatrics, 2024, 38(5): 461-437.
[8]	LIU Qianhui, YAO Zijun, HE Yuli, XU Yunfan, WU Jun. Effects of HbA1c level on cardiac structure and function in elderly patients with type 2 diabetes mellitus and chronic heart failure [J]. Practical Geriatrics, 2024, 38(5): 491-437.
[9]	SHI Pengfei, LI Na, YE Shuo, LIU Yaoming, BAI Jie. Establishment of a nomogram prediction model for the risk of heart failure during perioperative period in elderly patients undergoing hip replacement [J]. Practical Geriatrics, 2024, 38(4): 358-361.
[10]	CHEN Shan, ZHONG Chongxia, LIU Yihai, ZOU Renfang, XU Biao, NI Jie, SHA Dujuan. Association of FT3 with readmissions due to heart failure in elderly patients with ischemic cardiomyopathy and heart failure [J]. Practical Geriatrics, 2024, 38(4): 382-385.
[11]	CHENG Qing, XU Yan, CHEN Guofei, DENG Xinyue. Correlation of serum angiotensin Ⅱ and nitric oxide levels with cognitive dysfunction in elderly patients with chronic heart failure [J]. Practical Geriatrics, 2024, 38(2): 132-135.
[12]	GAO Wenjun, SUN Qing, LIU Mengtan, ZHOU Dan. Analysis of the current situation and influencing factors of demoralization syndrome in elderly patients with chronic heart failure [J]. Practical Geriatrics, 2024, 38(11): 1105-1109.
[13]	YAN Hongjuan, SHI Pengxiao, SONG Yuanyuan, LI Yan, FENG Lisa, LUO Qiuhua. Establishment of prediction model of death risk in elderly patients with chronic heart failure treated with ARNI [J]. Practical Geriatrics, 2024, 38(11): 1116-1120.
[14]	OU Dongbo, WANG Qi, FENG Guangqin, LI Wei, HUANG Xiaolian, WEI Li. Therapeutic effect of enhanced exetrnal counterpulsation therapy in elderly patients with chronic heart failure and renal insufficiency [J]. Practical Geriatrics, 2024, 38(11): 1131-1135.
[15]	GU Chonghuai, XIANG Xuejun, ZHENG Yuanxi, QIAO Rui, LIN Song. Efficacy of dapagliflozin in elderly patients undergoing coronary intervention with type 2 diabetes mellitus and ejection fraction reduced heart failure [J]. Practical Geriatrics, 2024, 38(10): 1025-1029.

Research progress on the cardioprotective effect of SGLT2 inhibitors through Na+/H+ exchanger

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

Research progress on the cardioprotective effect of SGLT2 inhibitors through Na⁺/H⁺ exchanger